BiotechTubeBiotechTube
Home/Pipeline/AVT33 (pembrolizumab biosimilar)

AVT33 (pembrolizumab biosimilar)

Oncology

Early PhaseIn Development

Key Facts

Indication
Oncology
Phase
Early Phase
Status
In Development
Company
Alvotech

About Alvotech

Alvotech is a purpose-driven biosimilar company with a mission to improve lives by expanding global access to affordable biologic medicines. The company leverages a fully integrated platform from cell line development to commercial manufacturing to achieve speed and control. Its strategic pipeline includes several approved biosimilars, such as AVT02 (adalimumab), and a deep portfolio targeting major immunology and oncology drugs. Alvotech is publicly traded and partners with commercialization experts to bring its products to market worldwide.

View full company profile

Therapeutic Areas

ImmunologyOncologyOphthalmologyBone DiseaseRespiratory

Other Oncology Drugs

DrugCompanyPhase
Mvasi (bevacizumab biosimilar)ViatrisApproved
DRL-17822Dr. Reddy's LaboratoriesPhase 2
Biosimilar PortfolioZydus LifesciencesVarious
therascreen Solid TumorQiagenCommercial
GBR 830Glenmark PharmaceuticalsPhase 1
Bevacizumab BiosimilarGlenmark PharmaceuticalsApproved
Biosimilar (Bevacizumab)Ipca LaboratoriesDevelopment
LockBody Platform AssetsCentessa PharmaceuticalsPre-clinical
EverolimusAmneal PharmaceuticalsApproved
Lenalidomide (Revlimid generic)Amneal PharmaceuticalsApproved
Alymsys (bevacizumab-maly)Amneal PharmaceuticalsApproved
Pemrydi RTUAmneal PharmaceuticalsApproved